-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US19243B1026 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 1.0 |
|---|---|
| Market Cap | 23M |
| Target Price | 5.4 |
| PE Ratio | None |
| Dividend Yield | None |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CGTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025